



FDA teases faster approval times with new agency-wide AI tool

July 17, 2025

James R. Ravitz | Marissa Hill Daley | Nathan Gray

SUMMARY

The US Food and Drug Administration (FDA) [launched](#) Elsa, a generative artificial intelligence (AI) tool designed to assist FDA employees with tasks such as reading, writing, and summarizing. The press release on the tool's launch states that FDA is already using the tool to accelerate clinical protocol reviews, speed up scientific evaluations, support safety profile assessments, and identify high-priority inspection targets. FDA's May 8, 2025, [announcement](#) that it would be ramping up use of AI across all centers teased faster regulatory approvals as a result, along with a quote from FDA Commissioner Dr. Martin A. Makary stating FDA's widespread adoption of AI "hold[s] tremendous promise in accelerating the review time for new therapies."

IN DEPTH

The launch of Elsa comes less than a month after FDA Commissioner Makary directed all FDA centers to begin deploying AI, with a stated target of full integration of AI across the agency by June 30, 2025. The use of AI allows scientific-review tasks that typically take days to complete to be performed within minutes. FDA states it is already using Elsa to summarize adverse events as part of safety profile assessments, identify high-priority inspection targets, perform label comparison, speed up clinical protocol reviews, and accelerate scientific evaluations. Elsa can also generate code that can be used to help develop databases for nonclinical applications. FDA intends to evaluate further use cases for Elsa and other AI tools moving forward, with data processing and generative AI functions as an early focus.

FDA appears confident that generative AI could allow its scientists and other experts to reduce the time spent on repetitive tasks that slow down the review process. FDA Commissioner Makary indicated that AI tools could help reduce "the amount of non-productive busywork that has historically consumed much of the review process." Like FDA's bid to phase out animal testing, which we previously [covered](#), this initiative is the latest in a series of efforts at FDA that the agency claims have the potential to reduce approval times for new therapies.

Elsa is the latest example of the agency's willingness to engage with AI's impact on the industry. We previously [addressed](#) two draft guidance documents released by FDA in January 2025 that address AI-enabled device software



functions and the use of AI to support regulatory submissions related to drugs and biologics. These guidance documents are the latest in a series of workshops, discussion papers, and guidance on the use of AI from FDA. FDA's focus on the technology does not appear to be waning, with FDA Commissioner Makary recently [commenting](#) that the agency will have to think creatively about how it regulates new AI technologies. Elsa demonstrates that FDA is taking this concept a step further and adopting AI within its own processes.

Elsa is powered by large language models (LLMs) and built within a high-security GovCloud environment that FDA says allows agency staff to securely access internal documents while ensuring the data remains within the agency. According to FDA, Elsa's models were not trained on data submitted by regulated industries.

McDermott will continue to monitor FDA's AI rollout and how it may impact the agency's review times for new therapies and ongoing oversight activities for existing therapies. If you have any questions about FDA's recent actions or about the FDA review process, please contact a member of McDermott's [Food, Drug & Medical Device Regulatory Group](#).

GET IN TOUCH

James R. Ravitz

[View Profile](#)

Marissa Hill Daley

[View Profile](#)

Nathan Gray

[View Profile](#)

This material is for general information purposes only and should not be construed as legal advice or any other advice on any specific facts or circumstances. No one should act or refrain from acting based upon any information herein without seeking professional legal advice. McDermott Will & Emery* (McDermott) makes no warranties, representations, or claims of any kind concerning the content herein. McDermott and the contributing presenters or authors expressly disclaim all liability to any person in respect of the consequences of anything done or not done in reliance upon the use of contents included herein. *For a complete list of McDermott entities visit mwe.com/legalnotices.

©2025 McDermott Will & Emery. All rights reserved. Any use of these materials including reproduction, modification, distribution or republication, without the prior written consent of McDermott is strictly prohibited. This may be considered attorney advertising. Prior results do not guarantee a similar outcome.